These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 19295335)

  • 1. Cardiovascular complications in HIV management: past, present, and future.
    Aberg JA
    J Acquir Immune Defic Syndr; 2009 Jan; 50(1):54-64. PubMed ID: 19295335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
    Kotler DP
    J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risks of antiretroviral therapies.
    Mondy K; Tebas P
    Annu Rev Med; 2007; 58():141-55. PubMed ID: 17217329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing cardiovascular risk in patients with HIV infection.
    Stein JH
    J Acquir Immune Defic Syndr; 2005 Feb; 38(2):115-23. PubMed ID: 15671795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine.
    Podzamczer D
    AIDS Rev; 2013; 15(4):195-203. PubMed ID: 24192600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.
    Lipshultz SE; Mas CM; Henkel JM; Franco VI; Fisher SD; Miller TL
    Expert Rev Anti Infect Ther; 2012 Jun; 10(6):661-74. PubMed ID: 22734956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies.
    Bozkurt B
    Cardiovasc Toxicol; 2004; 4(3):243-60. PubMed ID: 15470272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
    Barbaro G
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study.
    Diaz-Zamudio M; Dey D; LaBounty T; Nelson M; Fan Z; Szczepaniak LS; Hsieh BP; Rajani R; Berman D; Li D; Dharmakumar R; Hardy WD; Conte AH
    J Cardiovasc Magn Reson; 2015 Oct; 17():91. PubMed ID: 26520571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular complications of HIV infection and treatment.
    Garg H; Joshi A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Mar; 11(1):58-66. PubMed ID: 22946901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease risk factors in HIV-infected patients in the HAART era.
    Galli M; Ridolfo AL; Gervasoni C
    Ann N Y Acad Sci; 2001 Nov; 946():200-13. PubMed ID: 11762987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk among HIV-positive patients on antiretroviral therapy.
    Aberg JA
    J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease associated with human immunodeficiency virus: a review.
    Costa LA; Almeida AG
    Rev Port Cardiol; 2015; 34(7-8):479-91. PubMed ID: 26162286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.
    Anuurad E; Semrad A; Berglund L
    Metab Syndr Relat Disord; 2009 Oct; 7(5):401-10. PubMed ID: 19355810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.